| (Values in U.S. Thousands) | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
| Sales | 593,640 | 564,690 | 537,270 | 567,980 | 596,070 |
| Sales Growth | +5.13% | +5.10% | -5.41% | -4.71% | +11.14% |
| Net Income | 208,210 | 543,990 | 102,000 | 4,780 | 494,340 |
| Net Income Growth | -61.73% | +433.32% | +2,033.89% | -99.03% | +585.54% |
Royalty Pharma Plc Cl A (RPRX)
31.05 x 1 31.95 x 3
Post-market by (Cboe BZX)
31.37 -0.28 (-0.88%) 03/28/25 [NASDAQ]
31.05 x 1 31.95 x 3
Post-market 31.37 unch (unch) 16:07 ET
for Fri, Mar 28th, 2025
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
Fiscal Year End Date: 12/31